After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
The Q & A document from the Reentry Changes Webinar hosted on 06/06/18 has been posted in the Wh...
We received an updated WNV package insert; please note the manufacturer and license number has been ...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...